Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Denali Therapeutics Inc.

http://www.denalitherapeutics.com

Latest From Denali Therapeutics Inc.

Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks

The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.

Clinical Trials Neurology

REGENXBIO Hunts For 2025 Gene Therapy Approval

The group’s gene therapy reduces saccharide levels in the rare childhood disease known as Hunter syndrome, but a confirmatory trial will be needed.

Clinical Trials Commercial

Eisai’s Alzheimer’s Pipeline Offers Combination Therapy Potential

Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.

Clinical Trials Neurology

Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out

The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.

Approvals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • F-star Gamma
    • Incro Pharmaceuticals
UsernamePublicRestriction

Register